David Steinberg
General Partner at Longwood Fund
Milton, Massachusetts
Overview
Work Experience
General Partner
2019 - Current
Venture Partner
2018 - 2019
Longwood Fund finances science-based companies that develop novel solutions for medical problems.
Chairman, Founding CEO
2021
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
Raised $75,000,000.00 from Longwood Fund, MRL Ventures Fund, 8VC, Omega Funds, MPM Capital, Mass General Brigham Ventures, Eli Lilly & Company Foundation, Heritage Medical Systems, Arkin Bio Ventures and Ono Venture Investment.
Board Member, Founding CEO
2022
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
Raised $38,000,000.00 from Cystic Fibrosis Foundation, Longwood Fund, Astellas Venture Management, Solasta Ventures, Camford Capital, Agent Capital and UTokyo Innovation Platform.
Board Member
2021
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Raised $100,000,000.00 from Forbion Capital Partners, Longwood Fund, Omega Funds and Atlas Venture.
Chairman, Founding CEO
2020
Be Biopharma (www.be.bio) is a leader in developing B cells as medicines, treating disease with the human body’s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, re-dosable and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, MD, and Richard James, PhD, Be Biopharma is re-imagining medicine based on the power of B cell therapy
Be Biopharma is developing B ceaBe Biopharma is a biotech research company that develops a class of B cells as medicines.lls as medicines.
Raised $264,000,000.00 from Longwood Fund, Bristol-Myers Squibb, Alta Partners, Atlas Venture, RA Capital Management, Takeda Ventures and ARCH Venture Partners.
Board Member
2020
Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.
Raised $116,000,000.00 from Catalio Capital Management, Longwood Capital Partners, Longitude Capital, Biotechnology Value Fund, Alta Partners and Frazier Life Sciences.
Founding CEO, former Chairman
2019 - 2021
Pyxis Oncology (NASDAQ:PYXS) is developing therapeutics to promote the body's immune response to cancer, based on new insights into the tumor microenvironment. www.pyxisoncology.com
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Raised $224,000,000.00 from StemPoint Capital, Deep Track Capital, Blue Owl, Ridgeback Capital and Laurion Capital Management.
Co-Founder
2017 - 2020
Targeting the biology of aging to prevent or treat aging-related diseases
Founding CEO
2016 - 2018
Vor Biopharma (NASDAQ:VOR) is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells.
Founding CEO
2011 - 2018
Rationally designing medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal immunology, and human interventional studies.
Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.
Raised $436,994,519.00 from CARB-X.